Abstracts tagged "Outcome measures"

Abstract Number: 1367 • ACR Convergence 2022
Patient and Physician Reported Outcomes of Juvenile Systemic Sclerosis Patients Significantly Improve over 12 Months Observation Period in the Juvenile Systemic Scleroderma Inception Cohort
Ivan Foeldvari¹, Jens Klotsche², Ozgur Kasapcopur³, Amra Adrovic⁴, Kathryn Torok⁵, Maria Teresa Terreri⁶, Brian Feldman⁷, Jordi Anton⁸, Maria Katsicas⁹, Valda Stanevica¹⁰, FLAVIO SZTAJNBOK¹¹, Simone Appenzeller¹², Tadey Avcin¹³, Mikhail Kostik¹⁴, Edoardo Marrani¹⁵, Walter Alberto Sifuentes-Giraldo¹⁶, Sindu Johnson¹⁷, Raju Khubchandani¹⁸, Dana Nemcova¹⁹, Maria José Santos²⁰, Cristina Battagliotti²¹, Lillemor Berntson²², Blanca Bica²³, Jürgen Brunner²³, Rolando Cimaz²⁴, Despina Eleftheriou²⁵, Liora Harel²⁶, Gerd Horneff²⁷, Mahesh Janarthanan²⁸, Tilmann Kallinich²⁹, Kirsten Minden³⁰, Anjali Patwardhan³¹, Dieneke Schonenberg-Meinema³², Vanessa Smith³³ and Nicola Helmus³⁴, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Turkey, ⁴Cerrahpaşa Medical School, Istanbul University, Istanbul, Turkey, ⁵Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ⁶Universidad Federal São Paulo, São Paulo, Brazil, ⁷Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁸Pediatric Rheumatology, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain, ⁹Hospital Garrahan, Buenos Aires, Argentina, ¹⁰Children's Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, ¹¹UFRJ/UERJ, São Paulo, Brazil, ¹²Unicamp, Campinas, São Paulo, Brazil, ¹³University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, ¹⁴Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ¹⁵University of Florence, Firenze, Italy, ¹⁶Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁷University of Toronto, Toronto, ON, Canada, ¹⁸SRCC Children's Hospital, Mumbai, India, ¹⁹Charles University, Prague, Czech Republic, ²⁰Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, ²¹Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, ²²Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, ²³UNIVERSIDADE FEDERAL DO RIO DE JANEIRO, Rio de Janeiro, Brazil, ²⁴University of Milano, Milano, Italy, ²⁵Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, ²⁶Schneider Children's Medical center, Tel Aviv University, Nettnja, Israel, ²⁷Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ²⁸SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, India, ²⁹Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ³⁰Charité Universitätsmedizin Berlin, Berlin, Germany, ³¹University of Missouri, Columbia, MO, ³²Emma Children’s Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ³³Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium, ³⁴Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children. The Juvenile Systemic Scleroderma Inception cohort…
Abstract Number: 1779 • ACR Convergence 2022
Psychosocial and Health Measures in Systemic Lupus Erythematosus: COVID-19 Pandemic Trends in the Georgians Organized Against Lupus Cohort
Charmayne Dunlop-Thomas¹, Gaobin Bao², Jessica Williams², S. Sam Lim¹ and Cristina Drenkard¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA
Background/Purpose: The COVID-19 pandemic may have a sustained impact on systemic lupus erythematosus (SLE) patients in multiple ways. In a large predominantly Black SLE cohort,…
Abstract Number: 2055 • ACR Convergence 2022
SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?
Alfredo Aguirre¹, Mimi Kim², Kosalaram Goteti³, Ying Li³, Amy Kao⁴, Nathalie Franchimont⁵, George Kong⁵, Catherine Barbey⁶, Qing Zuraw⁷, Robert Gordon⁷, David Manner⁸, Maria Silk⁹, Teodora Staeva¹⁰, Hoang Nguyen¹¹, Richard Furie¹², Matthew Linnik¹³ and Maria Dall'Era¹⁴, ¹University of California, San Francisco, San Francisco, CA, ²Albert Einstein College of Medicine, Larchmont, NY, ³EMD Serono, Boston, MA, ⁴EMD Serono, Billerica, MA, ⁵Biogen, Cambridge, MA, ⁶Biogen, Baar, Switzerland, ⁷Janssen Research and Development, LLC, Spring House, PA, ⁸Eli Lilly and Company, Indianapolis, IN, ⁹Eli Lilly, Carmel, IN, ¹⁰Lupus Research Alliance, New York, NY, ¹¹Lupus Research Alliance, Houston, TX, ¹²Northwell Health, Great Neck, NY, ¹³Eli Lilly and Company, San Diego, CA, ¹⁴University of California, Division of Rheumatology, San Francisco, CA
Background/Purpose: The Systemic Lupus Erythematosus Responder Index 4 (SRI-4) and the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) are currently the most…
Abstract Number: 0065 • ACR Convergence 2022
Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care
Tarun Sharma¹, paul lebovitz¹, chetan rajput², Lori Mcaninch³, ellen Kraemer³, izabela Stanescu³, adam dore¹, joseph ahearn³ and Susan Manzi⁴, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, ³Allegheny Health Network, Pittsburgh, ⁴Allegheny Health Network, Lupus Center of Excellence, Wexford, PA
Background/Purpose: Care transformation in a chronic illness like RA requires delivery of health care services through a patient-centric care model. Within an integrated delivery and…
Abstract Number: 0282 • ACR Convergence 2022
Efficacy and Safety of Upadacitinib in TNFi-IR Patients with Rheumatoid Arthritis from Three Phase 3 Clinical Trials
Roy Fleischmann¹, Louis Bessette², Jeffrey Sparks³, Stephen Hall⁴, Manish Jain⁵, Adriana Kakehasi⁶, Yanna Song⁷, Sebastian Meerwein⁸, Ryan DeMasi⁷, Jessica Suboticki⁹ and Andrea Rubbert-Roth¹⁰, ¹University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ²Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Emeritus Research and Monash University, Melbourne, Australia, ⁵Great Lakes Clinical Trials, Chicago, IL, ⁶Federal University of Minas Gerais, Hospital das Clínicas, Belo Horizonte, Brazil, ⁷AbbVie, Inc., North Chicago, IL, ⁸AbbVie Deutschland GmbH & Co KG, LUDWIGSHAFEN, Germany, ⁹AbbVie, Inc., Mettawa, IL, ¹⁰Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: For patients with RA who are refractory to biologic disease-modifying antirheumatic drugs (bDMARDs), such as tumor necrosis factor inhibitors (TNFis), optimal disease control is…
Abstract Number: 0710 • ACR Convergence 2022
Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study
Naomi Patel¹, Xiaosong Wang², Xiaoqing Fu³, Yumeko Kawano², Claire Cook³, Kathleen Vanni², Grace Qian², Emily Banasiak², Emily Kowalski², yuqing zhang⁴, Jeffrey Sparks⁵ and Zachary Wallace³, ¹Massachusetts General Hospital, Sale Creek, TN, ²Brigham and Women's Hospital, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Quincy, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Some patients with rheumatic disease on DMARDs may be at increased risk of poor response to SARS-CoV-2 vaccines and thus breakthrough COVID-19 infections. We…
Abstract Number: 1079 • ACR Convergence 2022
Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Vanesa Calvo Río², Javier Loricera³, Nuria Aviles⁴, Juan M Blanco Madrigal⁵, Santos Castañeda⁶, Miguel Angel Gonzalez Gay⁷ and Ricardo Blanco³, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Valdecilla Hospital, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Perpetuo Socorro, Albacete, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁷Hospital Universitario Marques de Valdecilla, Lugo, Spain
Background/Purpose: Anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is…
Abstract Number: 1370 • ACR Convergence 2022
Abatacept in the Treatment of Refractory Juvenile Dermatomyositis
Gulnara Mamyrova¹, William Nguyen², Hassan Awal¹, Derek Jones¹, Alison Ehrlich³, Kathleen Brindle⁴, Shahriar Haji-Momenian⁴, Robert Sheets⁵, Adeline Y. Chin⁶, Shajia Lu⁷, Massimo Gadina⁷, Hanna Kim⁸, Olcay Y. Jones⁹, Lisa G Rider¹⁰ and Rodolfo V Curiel¹, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Division of Rheumatology, Department of Medicine, George Washington University, School of Medicine and Health Sciences, Washington, DC, ³Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁴Department of Radiology, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁵Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of California San Diego, Rady Children's Hospital, San Diego, CA, ⁶Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁷Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ⁸Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Juvenile Myositis Therapeutic and Translation Studies Unit, PTRB, NIAMS, NIH, Bethesda, MD, ⁹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences; Pediatric Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁰Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD
Background/Purpose: This open-label 24-week study was conducted to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (JDM).Methods: Ten patients of…
Abstract Number: 1813 • ACR Convergence 2022
Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Mary Grace Whelan¹, Keigo Hayashi² and Sara Tedeschi¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease prevalence is similar to gout and osteoarthritis (OA), yet CPPD outcomes research greatly lags behind these other forms of…
Abstract Number: 2093 • ACR Convergence 2022
Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort
Farah Tamirou and Frédéric A. Houssiau, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Background/Purpose: While long-term follow-up (FU) is needed to unmask poor outcome in lupus nephritis (LN), most clinical trials evaluate outcome measures at short-term. Early endpoints…
Abstract Number: 0077 • ACR Convergence 2022
Rheumatoid Arthritis – Are We Getting to Target?
myint Thway¹, Gurjit S. Kaeley², Karishma Ramsubeik³, Laurie Ramrattan¹, Lilian Otalora Rojas⁴ and Sukhraj Singh¹, ¹University of Florida-Jacksonville, Jacksonville, FL, ²UF COM-J, Ponte Vedra Beach, FL, ³University of Florida, Jacksonville, FL, ⁴University of Florida, Ponte Vedra Beach, FL
Background/Purpose: Low disease activity (LDA) is a key goal in treating Rheumatoid arthritis, but implementing the treat to target approach in clinical practice has been…
Abstract Number: 0285 • ACR Convergence 2022
Characteristics and Outcomes of Patients with Rheumatoid Arthritis Treated with Upadacitinib in a Global Real-World Setting
Roberto Felice Caporali¹, Jayeshkumar Patel², Oliver Howell³, sander strengholt⁴, Hannah Jones³ and Peter Taylor⁵, ¹University of Milan, Milano, Italy, ²AbbVie, Inc., North Chicago, IL, ³Adelphi Real World, Bollington, United Kingdom, ⁴AbbVie, Inc., Abcoude, Netherlands, ⁵University of Oxford, Oxford, United Kingdom
Background/Purpose: Upadacitinib (UPA), a Janus kinase inhibitor, is a newly approved advanced therapy for patients (pts) with rheumatoid arthritis (RA), thus real-world evidence is lacking.…
Abstract Number: 0722 • ACR Convergence 2022
Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry
Alejandro Brigante¹, Rosana Quintana², Carolina Isnardi³, Karen Roberts⁴, Gimena Gomez⁵, Maria Haye Salinas⁶, Enrique Soriano⁷, Guillermo Pons-Estel⁸, Maria De la Vega⁸, Osvaldo kerzberg⁷, Julieta Gamba⁷, Anastasia Secco⁹, Gustavo Citera¹⁰, Cesar Graf⁷, Veronica Savio¹¹, Maria de los Angeles Gallardo⁷, Nora Aste⁷, Mercedes A Garcia¹², Gustavo Casado⁷, Carla Gobbi⁷, Graciela Gomez⁷, Joan Manuel Dapeña¹³, Guillermo Berbotto⁷, Malena Viola⁷, Jonathan Rebak⁷, Diana Dubinsky⁷, Veronica Saurit¹⁴, Ingrid Petkovic⁷, Ana Bertoli⁷, Erika Catay⁷, C Leoni⁷, Ida Elena Exeni⁷, Bernardo Pons-Estel¹⁵, Sergio Paira⁷, GH Bovea Castelblanco⁷, Mercedes De la Sota⁷, Dora Pereira⁷, Gustavo Medina⁷, Amelia Granel⁷, Maria s Larroude⁷, Analia Patricia Alvarez⁷, Santiago Agüero¹⁶, Cecilia Pisoni¹⁷, Monica Sacnun⁷ and Edson Velozo¹⁸, ¹UNISAR, Lobos, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ³SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁴UNISAR, Rosario, Argentina, ⁵Sanatorio Guemes, Buenos Aires, Argentina, ⁶UNLAR, La Rioja, Argentina, ⁷On behalf of the BIOBADASAR 3.0 registry, Buenos Aires, Argentina, ⁸Argentine Society of Rheumatology, Buenos Aires, Argentina, ⁹Rivadavia Hospital, Buenos Aires, Argentina, ¹⁰Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, ¹¹Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, ¹²HIGA San Martin, La Plata, Argentina, ¹³Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina, ¹⁴Hospital Privado Universitario, Cordoba, Argentina, ¹⁵Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹⁶Centro de Rehabilitación Dr Mauricio Figueroa, Catamarca, Argentina, ¹⁷CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ¹⁸SAR COVID Investigator, Caba
Background/Purpose: Major adverse cardiovascular events (MACE) and neoplasms are a concern in autoimmune diseases. RA and PsA are diseases where inflammation plays a key role…
Abstract Number: 1084 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for Induction Therapy in Granulomatosis with Polyangiitis: A Target Trial Emulation Study
Xavier Puéchal¹, Michele Iudici², Elodie Perrodeau³, bernard bonnotte⁴, Francois Lifermann⁵, Thomas Le Gallou⁶, Alexandre Karras⁷, Claire Blanchard-Delaunay⁸, Thomas Quéméneur⁹, Achille Aouba¹⁰, Olivier Aumaître¹¹, Vincent Cottin¹², Mohamed Hamidou¹³, Marc Ruivard¹¹, Pascal Cohen¹, Luc Mouthon¹, Loïc Guillevin¹, Philippe Ravaud³, Raphaël Porcher³ and Benjamin Terrier¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ³Université Paris Cité, Hôtel-Dieu, Paris, France, ⁴Centre Hospitalo-Universitaire de Dijon, Dijon, France, ⁵Dax Hospital, Dax, France, ⁶Rennes Sud University Hospital, Rennes, France, ⁷HEGP, Paris, France, ⁸Niort Hospital, Niort, France, ⁹Valenciennes Hospital, Valenciennes, France, ¹⁰Department of Internal Medicine, UR4650 PSIR, Normandie Univ, UNICAEN, CHU de Caen Normandie, Caen, France, ¹¹Clermont Ferrand University Hospital, Clermont-Ferrand, France, ¹²Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹³Nantes University Hospital, Nantes, France
Background/Purpose: Randomized controlled trials showed rituximab (RTX)'s non-inferiority to cyclophosphamide (CYC) for induction therapy of ANCA-associated vasculitis and neither treatment was favoured in granulomatosis with…
Abstract Number: 1388 • ACR Convergence 2022
Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes
Anthony Dolomisiewicz¹, Hanifah Ali², Punyasha Roul³, Yangyuna Yang¹, Grant Cannon⁴, Joshua Baker⁵, Ted Mikuls⁶, Kaleb Michaud¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, ³UNMC, Omaha, NE, ⁴Salt Lake City VA, Salt Lake city, ⁵University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁶Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Rheumatic Disease Comorbidity Index (RDCI) was designed to quantify comorbidity burden for risk stratification of health outcomes in patients with rheumatic disease. Developed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].